<DOC>
	<DOCNO>NCT01835678</DOCNO>
	<brief_summary>Diabetes mellitus metabolic disease grow prevalence worldwide , affect 171 million people 2000 expect 366 million people 2030 ( 1 ) therefore diabetic nephropathy rapidly increase Western hemisphere represent 50 % cause end stage renal disease . Hence , early intervention desirable prevent damage kidney . In early stage diabetic nephropathy , endothelium dysfunction key pathogenetic process indicate increased leakage albumin glomerular barrier ( 2 ) . Hence , improvement endothelium function attractive therapeutic goal antidiabetic medication . Endothelial dysfunction , particular basal nitric oxide activity , also identify pivotal determinant glomerular filtration rate ( 3 ) . A new promising class antidiabetic drug gliptins . Gliptins act inhibit enzyme dipeptidyl peptidase-4 ( DPP-4 ) , responsible rapid inactivation glucagon-like peptide-1 ( GLP-1 ) - incretin hormone gut ( 6 - 8 ) , thereby enhance prolong effect GLP-1 . GLP-1 - member incretin hormone - release blood meal ingestion stimulate insulin secretion glucose dependent manner . This account marked prandial insulin response , prevent prandial hyperglycemia . Apart surrogate parameter like reduction fast postprandial blood glucose level improvement HbA1c , effect gliptins micro- macrovascular function cardiovascular outcome primary focus current study . However , infusion GLP-1 , incretin hormone affect gliptins report ameliorate endothelial dysfunction patient suffer coronary artery disease ( 9 ) recently show infusion GLP-1 healthy human subject increase normal ACh-induced vasodilatation ( 10 ) . In study rat diabetes , GLP-1 infusion nearly re-established normal vascular tone ( 11 ) data experimental animal indicate beneficial effect GLP-1 endothelial function ( 12 ) . It major interest whether therapy gliptins improve endothelial function micro- macrovasculature . In face burden diabetic nephropathy cause , effect linagliptin renal vasculature endothelium integrity renal circulation ( measured availability nitric oxide ) , key stone order claim linagliptin effective antidiabetic agent . There need demonstrate linagliptin effective beyond blood glucose lower action improve vascular endothelium function kidney .</brief_summary>
	<brief_title>Effects Linagliptin Renal Endothelium Function Patients With Type 2 Diabetes .</brief_title>
	<detailed_description>Diabetes mellitus metabolic disease grow prevalence worldwide , affect 171 million people 2000 expect 366 million people 2030 ( 1 ) therefore diabetic nephropathy rapidly increase Western hemisphere represent 50 % cause end stage renal disease . Hence , early intervention desirable prevent damage kidney . In early stage diabetic nephropathy , endothelium dysfunction key pathogenetic process indicate increased leakage albumin glomerular barrier ( 2 ) . Hence , improvement endothelium function attractive therapeutic goal antidiabetic medication . Endothelial dysfunction , particular basal nitric oxide activity , also identify pivotal determinant glomerular filtration rate ( 3 ) . Previously , blockade renin angiotensin system find effective improve endothelium function ( 4 ) . Furthermore , observed renal endothelium function improve cardiovascular risk factor control ( e.g . blood pressure ) may predictive development diabetic nephropathy ( 5 ) . A new promising class antidiabetic drug gliptins . Gliptins act inhibit enzyme dipeptidyl peptidase-4 ( DPP-4 ) , responsible rapid inactivation glucagon-like peptide-1 ( GLP-1 ) - incretin hormone gut ( 6 - 8 ) , thereby enhance prolong effect GLP-1 . GLP-1 - member incretin hormone - release blood meal ingestion stimulate insulin secretion glucose dependent manner . This account marked prandial insulin response , prevent prandial hyperglycemia . Several efficacy study demonstrate significant improvement HbA1c gliptins . In addition , gliptins improved fasting well prandial glucose level induce weight gain . Due positive metabolic effect combination small spectrum side effect gliptins might well part standard therapy type 2 diabetes future . Apart surrogate parameter like reduction fast postprandial blood glucose level improvement HbA1c , effect gliptins micro- macrovascular function cardiovascular outcome primary focus current study . However , infusion GLP-1 , incretin hormone affect gliptins report ameliorate endothelial dysfunction patient suffer coronary artery disease ( 9 ) recently show infusion GLP-1 healthy human subject increase normal ACh-induced vasodilatation ( 10 ) . In study rat diabetes , GLP-1 infusion nearly re-established normal vascular tone ( 11 ) data experimental animal indicate beneficial effect GLP-1 endothelial function ( 12 ) . Diabetes mellitus strongly associate microangiopathy macroangiopathy strong independent risk factor cardiovascular disease cardiovascular mortality ( 13 ) . Endothelial dysfunction play crucial role atherosclerotic process commonly observe patient diabetes mellitus already prediabetes - amongst factor - link fasting postprandial hyperglycemia . Gliptins reduce hyperglycemia hyperglycemic peak prevent inactivation GLP-1 , exert beneficial effect endothelium previous study . It major interest whether therapy gliptins improve endothelial function micro- macrovasculature . In face burden diabetic nephropathy cause , effect linagliptin renal vasculature endothelium integrity renal circulation ( measured availability nitric oxide ) , key stone order claim linagliptin effective antidiabetic agent . There need demonstrate linagliptin effective beyond blood glucose lower action improve vascular endothelium function kidney .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Female male patient age 18 70 year Type 2 diabetes without diabetic nephropathy ( definition see exclusion criterion ) Any form diabetes mellitus type 2 diabetes mellitus Use insulin , glitazone gliptins within past 3 month Any oral antidiabetic drug discontinue study period . Any history stroke , transient ischemic attack , instable angina pectoris , myocardial infarction within last 6 month prior study inclusion Urinary albumin excretion ( UACR ) &gt; 100 mg/g ( early morning spot urine ) eGFR &lt; 45 ml/min/1.73m² ( MDRD Formula ) Uncontrolled arterial hypertension ( RR ≥180/ ≥110mmHg ) HbA1c ≥ 10 % Fasting plasma glucose ≥ 240 mg/dl Body mass index ≥ 40 kg/m² Triglyceride level ≥ 1000 mg/dl HDLcholesterol level &lt; 25 mg/dl Overt congestive heart failure ( CHF ) history CHF Severe disorder gastrointestinal tract disease interfere pharmacodynamics pharmacokinetics study drug Significant laboratory abnormality SGOT SGPT level 3 x upper limit normal range , serum creatinine &gt; 2mg/dl Drug alcohol abuse Pregnant breastfeed patient Any patient currently receive chronic ( &gt; 30 consecutive day ) treatment oral corticosteroid Patients treat severe auto immune disease e.g . lupus Participation another clinical study within 30 day prior visit 1 Individuals risk poor protocol medication compliance Subject give write consent , pseudonymous data transfer line duty documentation duty notification accord § 12 § 13 GCPV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>